



**Health, Seniors and Long-Term Care  
Public Health**  
300 Carlton Street  
Winnipeg, Manitoba Canada R3B 3M9

July 4, 2024

**Re: Updated Guidance for Immunoprophylaxis of Group 1 Close Contacts in the Invasive Meningococcal Disease (*Neisseria meningitidis*) Management Protocol**

Dear Health Care Provider,

Manitoba Health, Seniors and Long-Term Care is providing additional guidance for immunoprophylaxis under section *8.21 Management of Group 1 Close Contacts* in the Invasive Meningococcal Disease (*Neisseria meningitidis*) Management Protocol (<https://www.gov.mb.ca/health/publichealth/cdc/protocol/mid.pdf>) as follows:

**Current statement on Page 4 under 8.21 Management of Group 1 Close Contacts:**

- Immunoprophylaxis should be considered when the case's serotype is known and vaccine preventable and the contact has not previously been immunized against that serotype.

**Updated guidance:**

- Immunoprophylaxis should be considered when the case's serogroup is known and vaccine preventable.
- Close contacts who were not previously immunized against the case's serogroup, or did not complete their primary series, should complete a primary series of the appropriate vaccine as soon as possible.
- Close contacts to a case of invasive meningococcal disease (IMD) caused by serogroup A, C, Y or W who were previously immunized with a full primary series of meningococcal vaccine that protects against the case's serogroup should be re-vaccinated with the following intervals:
  - If they were less than 1 year of age at last meningococcal vaccination, administer a dose of Men-C-ACYW vaccine at least **4 weeks** from their last meningococcal vaccine.
  - If they have an underlying medical condition that puts them at risk for IMD, administer a dose of Men-C-ACYW vaccine at least **4 weeks** from their last meningococcal vaccine.
  - If they were more than 1 year of age at last meningococcal vaccination and are not at high risk for meningococcal disease, administer a dose of the Men-C-ACYW vaccine at least **a year** since their last meningococcal vaccine.
- Close contacts to a case of IMD caused by serogroup B should receive a dose of meningococcal B vaccine at least **4 weeks** after their last dose. If they did not previously complete a primary series, the series should be completed.

(Please check Canadian Immunization Guide, Meningococcal Vaccines Chapter, Table 2: Recommended vaccination of close contacts for post-exposure management and for outbreak control - <https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-13-meningococcal-vaccine.html#t2> for more information.)

Any questions regarding these changes can be emailed to [vaccines@gov.mb.ca](mailto:vaccines@gov.mb.ca).

Please share this information with all relevant colleagues in your facility.

Sincerely,

*“Original signed by:”*

Richard Baydack, PhD  
Director  
Communicable Disease Control

*“Original signed by:”*

Natalie Casclang, MD, CCFP, FRCPC  
Medical Officer of Health,  
Population and Public Health